Broadwood Partners, L.P., 10% Owner at Insight Molecular Diagnostics Inc. (IMDX), bought 182,861 shares at $3.45 ($653K) on 2026-04-16, disclosed to the SEC on 2026-04-20.
Broadwood Partners, L.P., a 10% holder, executed the largest insider purchase in IMDX's history by buying 102,057 shares at $3.45 on April 16, 2026. This move coincides with a 33% five-day rally and signals confidence in the company's recent capital raise and upcoming regulatory catalysts.
IMDX has surged 33% over the past five days but remains down 6.34% over the last month, currently trading 35.54% below its 52-week high of $6.19.
The upcoming FDA submission for GraftAssureDx is a key catalyst, highlighted in analyst commentary from April 13 and April 29 alongside a $26M capital raise. Furthermore, the analyst price target has been raised to $12 per share in updates from April 13 and May 15, driven by funding visibility.
Risks include a short interest of 4.5% and a Q4 2025 loss of $23 million, as reported in the March 26 earnings snapshot.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $3.45 | 102,057 | $352K | 53.9% |
| 2 | $3.57 | 40,114 | $143K | 21.9% |
| 3 | $3.88 | 40,690 | $158K | 24.2% |
| Total | $3.57 avg | 182,861 | $653K | 100% |
| Filing → |
| STAA | BUY | 2026-01-08 | $8.8M | — | Filing → |
| STAA | BUY | 2025-04-07 | $27.2M | — | Filing → |
| STAA | BUY | 2025-04-02 | $1.9M | — | Filing → |